- Viscosupplementation, involving the injection of hyaluronic acid into synovial joints, is increasingly recognized as an effective treatment option for osteoarthritis-related joint pain, particularly in the knee, due to its ability to restore joint lubrication and improve mobility without the need for surgery
- The rising demand for viscosupplementation across Europe is primarily driven by the growing geriatric population, increasing prevalence of osteoarthritis, and a strong preference for non-invasive, outpatient-based pain management therapies
- Germany dominated the viscosupplementation market with the largest revenue share of 42% in 2024, supported by its advanced healthcare infrastructure, significant aging population, and early adoption of non-surgical orthopedic treatments
- Turkey is expected to be the fastest growing country in the viscosupplementation market during the forecast period due to its expanding healthcare sector, increasing access to advanced therapies, and rising public awareness about minimally invasive osteoarthritis treatments
- The single-injection segment dominated the viscosupplementation market with a market share of 46.3% in 2024, owing to its convenience, reduced treatment burden on patients, and comparable efficacy to multi-injection regimens
